O Dell Group LLC Has $417,000 Stock Holdings in Johnson & Johnson (NYSE:JNJ)

O Dell Group LLC decreased its holdings in shares of Johnson & Johnson (NYSE:JNJGet Rating) by 21.5% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 2,350 shares of the company’s stock after selling 644 shares during the quarter. O Dell Group LLC’s holdings in Johnson & Johnson were worth $417,000 at the end of the most recent reporting period.

Several other hedge funds have also added to or reduced their stakes in JNJ. RE Dickinson Investment Advisors LLC lifted its holdings in Johnson & Johnson by 163.3% during the 1st quarter. RE Dickinson Investment Advisors LLC now owns 158 shares of the company’s stock valued at $28,000 after purchasing an additional 98 shares during the last quarter. Advanced Research Investment Solutions LLC lifted its holdings in shares of Johnson & Johnson by 200.0% during the first quarter. Advanced Research Investment Solutions LLC now owns 180 shares of the company’s stock worth $32,000 after buying an additional 120 shares in the last quarter. Morton Brown Family Wealth LLC lifted its holdings in shares of Johnson & Johnson by 78.0% during the second quarter. Morton Brown Family Wealth LLC now owns 178 shares of the company’s stock worth $32,000 after buying an additional 78 shares in the last quarter. Professional Financial Advisors LLC lifted its holdings in shares of Johnson & Johnson by 47.9% during the first quarter. Professional Financial Advisors LLC now owns 210 shares of the company’s stock worth $37,000 after buying an additional 68 shares in the last quarter. Finally, Goodman Advisory Group LLC acquired a new stake in shares of Johnson & Johnson during the second quarter worth $39,000. Institutional investors and hedge funds own 68.59% of the company’s stock.

Analyst Ratings Changes

JNJ has been the subject of a number of research reports. Sanford C. Bernstein dropped their target price on Johnson & Johnson from $194.00 to $190.00 in a report on Wednesday, October 19th. Barclays initiated coverage on Johnson & Johnson in a report on Monday, October 17th. They set an “equal weight” rating and a $175.00 target price for the company. StockNews.com initiated coverage on Johnson & Johnson in a report on Wednesday, October 12th. They set a “strong-buy” rating for the company. Atlantic Securities decreased their price target on Johnson & Johnson from $165.00 to $160.00 and set a “neutral” rating on the stock in a research report on Wednesday, October 19th. Finally, Morgan Stanley decreased their price target on Johnson & Johnson from $174.00 to $170.00 and set an “equal weight” rating on the stock in a research report on Wednesday, October 19th. Seven equities research analysts have rated the stock with a hold rating, four have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $181.33.

Johnson & Johnson Stock Performance

Johnson & Johnson stock opened at $177.01 on Thursday. Johnson & Johnson has a 12-month low of $155.72 and a 12-month high of $186.69. The company has a quick ratio of 1.18, a current ratio of 1.43 and a debt-to-equity ratio of 0.37. The business’s 50-day moving average price is $168.35 and its two-hundred day moving average price is $171.28. The stock has a market cap of $462.79 billion, a PE ratio of 24.65, a P/E/G ratio of 3.49 and a beta of 0.57.

Johnson & Johnson (NYSE:JNJGet Rating) last released its earnings results on Tuesday, October 18th. The company reported $2.55 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.49 by $0.06. Johnson & Johnson had a return on equity of 35.37% and a net margin of 19.95%. The firm had revenue of $23.79 billion for the quarter, compared to analysts’ expectations of $23.44 billion. During the same quarter in the previous year, the business posted $2.60 earnings per share. The business’s revenue for the quarter was up 1.9% on a year-over-year basis. As a group, analysts expect that Johnson & Johnson will post 10.04 earnings per share for the current fiscal year.

Johnson & Johnson Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, December 6th. Shareholders of record on Tuesday, November 22nd will be given a $1.13 dividend. This represents a $4.52 dividend on an annualized basis and a yield of 2.55%. The ex-dividend date of this dividend is Monday, November 21st. Johnson & Johnson’s dividend payout ratio is presently 62.95%.

Johnson & Johnson announced that its board has authorized a stock buyback program on Wednesday, September 14th that permits the company to buyback $5.00 billion in outstanding shares. This buyback authorization permits the company to repurchase up to 1.2% of its stock through open market purchases. Stock buyback programs are usually an indication that the company’s management believes its stock is undervalued.

Insider Buying and Selling at Johnson & Johnson

In other news, EVP Jennifer L. Taubert sold 76,923 shares of the business’s stock in a transaction dated Tuesday, November 22nd. The stock was sold at an average price of $176.78, for a total transaction of $13,598,447.94. Following the sale, the executive vice president now directly owns 126,456 shares in the company, valued at $22,354,891.68. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. In other news, CAO Robert J. Decker sold 16,928 shares of the business’s stock in a transaction dated Friday, November 18th. The stock was sold at an average price of $175.00, for a total transaction of $2,962,400.00. Following the sale, the chief accounting officer now directly owns 15,473 shares in the company, valued at $2,707,775. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, EVP Jennifer L. Taubert sold 76,923 shares of the business’s stock in a transaction dated Tuesday, November 22nd. The stock was sold at an average price of $176.78, for a total value of $13,598,447.94. Following the sale, the executive vice president now owns 126,456 shares in the company, valued at $22,354,891.68. The disclosure for this sale can be found here. Insiders have sold a total of 212,646 shares of company stock worth $36,791,022 over the last 90 days. Insiders own 0.35% of the company’s stock.

About Johnson & Johnson

(Get Rating)

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR.

See Also

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.